Immunotherapeutic approach on triple negative breast cancer: recent progress and predictors of response

doi:10.3877/cma.j.issn.1674-0807.2022.04.001

中华乳腺病杂志(电子版) ›› 2022, Vol. 16 ›› Issue (04) : 199 -203. doi: 10.3877/cma.j.issn.1674-0807.2022.04.001

专家论坛

Immunotherapeutic approach on triple negative breast cancer: recent progress and predictors of response

Louis Wing-Cheong Chow¹^,^†(

), Erich Ferdiansyah Lie²

^1. UNIMED Medical Institute, Hong Kong, China；Organisation for Oncology and Translational Research, Hong Kong, China
^2. UNIMED Medical Institute, Hong Kong, China

收稿日期:2022-02-10 出版日期:2022-08-01
通信作者: Louis Wing--Cheong Chow

Immunotherapeutic approach on triple negative breast cancer: recent progress and predictors of response

Louis Wing-Cheong Chow¹(), Erich Ferdiansyah Lie²

Received:2022-02-10 Published:2022-08-01
Corresponding author: Louis Wing--Cheong Chow

全文 ( ) 下载PDF ( ) 导出引用

Clinical trials utilizing the immune checkpoint inhibitors, particularly the IMpassion and KEYNOTE trials, have made it possible to understand how the immune checkpoint inhibitors can be used to treat patients with triple negative breast cancer (TNBC). Patient stratification based on simply PD-L1 positivity has now been shown to be insufficient and inaccurate as a predictor of response to the immune checkpoint inhibitors, and the role of the tumor microenvironment has become more apparent. This article serves as a brief overview of the latest progress on the clinical trials as well as the potential predictors of response to immune checkpoint blockade.

关键词: Triple negative breast cancer, Immunotherapy, Microenvironment

Table 1 Selected clinical trials assessing immune checkpoint inhibitors for treating TNBC

Trial name	Study design	Phase	Cases	Reference(s)
IMpassion 130	Atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel for untreated, metastatic TNBC	3	451 vs 451(1∶1 ratio)	[4,5,6]
IMpassion 131	Atezolizumab plus paclitaxel vs placebo plus paclitaxel for untreated, advanced TNBC	3	431 vs 220(2∶1 ratio)	[7]
KEYNOTE-355	Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for untreated, locally recurrent inoperable or metastatic TNBC	3	566 vs 281(2∶1 ratio)	[8,9]
KEYNOTE-522	Pembrolizumab plus paclitaxel and carboplatin vs placebo plus paclitaxel and carboplatin, followed by adjuvant pembrolizumab vs placebo after surgery, for untreated, stage 2 or 3 TNBC	3	784 vs 390(2∶1 ratio)	[10,11]
FUTURE-C-PLUS	Camrelizumab plus famitinib for immunomodulatory-advanced, untreated, advanced TNBC	2	48(single-arm)	[12]

Table 1 Selected clinical trials assessing immune checkpoint inhibitors for treating TNBC

Trial name	Study design	Phase	Cases	Reference(s)
IMpassion 130	Atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel for untreated, metastatic TNBC	3	451 vs 451(1∶1 ratio)	[4,5,6]
IMpassion 131	Atezolizumab plus paclitaxel vs placebo plus paclitaxel for untreated, advanced TNBC	3	431 vs 220(2∶1 ratio)	[7]
KEYNOTE-355	Pembrolizumab plus chemotherapy vs placebo plus chemotherapy for untreated, locally recurrent inoperable or metastatic TNBC	3	566 vs 281(2∶1 ratio)	[8,9]
KEYNOTE-522	Pembrolizumab plus paclitaxel and carboplatin vs placebo plus paclitaxel and carboplatin, followed by adjuvant pembrolizumab vs placebo after surgery, for untreated, stage 2 or 3 TNBC	3	784 vs 390(2∶1 ratio)	[10,11]
FUTURE-C-PLUS	Camrelizumab plus famitinib for immunomodulatory-advanced, untreated, advanced TNBC	2	48(single-arm)	[12]

[1]	Bayraktar S, Batoo S, Okuno S, et al. Immunotherapy in breast cancer[J]. J Carcinog，2019，18：2.
[2]	Zhang J, Tian Q, Zhang M, et al. Immune-related biomarkers in triple-negative breast cancer[J]. Breast Cancer，2021，28(4)：792-805.
[3]	Zhao J, Huang J. Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1[J]. Chin Med J (Engl)，2020，133(7)：853-862.
[4]	Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J]. N Engl J Med，2018，379(22)：2108-2121.
[5]	Schmid P, Adams S, Rugo HS, et al. IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC) [J]. J Clin Oncol，2019，37(15_suppl)：1003.
[6]	Emens LA, Adams S, Barrios CH, et al. LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol，2020，31：S1148.
[7]	Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer[J]. Ann Oncol，2021，32(8)：994-1004.
[8]	Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet，2020，396(10 265)：1817-1828.
[9]	Cortes J, Cescon DW, Rugo HS, et al. LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC[J]. Ann Oncol，2021，32：S1289-1290.
[10]	Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med，2020，382(9)：810-821.
[11]	Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer[J]. N Engl J Med, 2022, 386(6)：556-567.
[12]	Li C, Shao Z, Wang Z, et al. Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study[J]. J Clin Oncol，2021，39(15_suppl)：1007.
[13]	Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer[J]. N Engl J Med, 2022，387(3)：217-226.
[14]	Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial[J]. Lancet Oncol，2019，20(3)：371-382.
[15]	Emens LA, Esteva FJ, Beresford M, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial[J]. Lancet Oncol，2020，21(10)：1283-1295.
[16]	Andersson A, Bergenstråhle J, Asp M, et al. Single-cell and spatial transcriptomics enables probabilistic inference of cell type topography[J]. Commun Biol，2020，3(1)：565.
[17]	Bianchini G, Wang X, Danenberg E, et al. Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial[J]. Cancer Res, 2022, 82(4_Supplement): GS1-00.
[18]	Dugo M, Huang C, Egle D, et al. Predictive value of RT-qPCR 27-gene IO score and comparison with RNA-Seq IO score in the NeoTRIPaPDL1 trial[J]. Cancer Res, 2022, 82 (4_Supplement): PD10-06.
[19]	Nielsen TJ, Ring BZ, Seitz RS, et al. A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies[J]. Heliyon，2021，7(3)：e06438.

No related articles found!

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Immunotherapeutic approach on triple negative breast cancer: recent progress and predictors of response

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Immunotherapeutic approach on triple negative breast cancer: recent progress and predictors of response